Table I.
Demographics and clinical characteristics of patients with thrombus diagnosed within 48 hours of hospital presentation stratified by COVID-19 diagnosis
| Variable | COVID-19 |
P value | |
|---|---|---|---|
| No (n = 164) | Yes (n = 48) | ||
| Demographics | |||
| Age, years | 64 (53-74) | 58 (50-66) | .043 |
| Female sex | 72 (43.9) | 15 (31.3) | .161 |
| BMI, kg/m2 | 27.8 (23.4-31.1) | 27.0 (23.4-31.5) | .83 |
| Comorbidities | |||
| Hypertension | 82 (50.0) | 23 (47.9) | .93 |
| Diabetes mellitus | 33 (19.5) | 11 (22.9) | .76 |
| Heart failure | 14 (8.6) | 1 (2.1) | .20 |
| Asthma | 8 (4.9) | 2 (4.2) | 1.00 |
| COPD | 10 (6.1) | 0 (0) | .12 |
| CKD | 17 (10.4) | 1 (2.1) | .08 |
| ESRD | 2 (1.2) | 0 (0) | 1.00 |
| Malignancy | 36 (22.0) | 2 (4.2) | .009 |
| HIV | 1 (1.1) | 0 (0) | 1.00 |
| Previous stroke | 15 (9.1) | 1 (2.1) | .13 |
| Previous MI | 7 (6.4) | 1 (2.1) | .44 |
| Previous VTE | 11 (9.9) | 3 (6.3) | .55 |
| Cigarette smoking | 43 (27.3) | 8 (17.0) | .22 |
| Electronic cigarette use (“vaping”) | 4 (2.8) | 0 (0) | .66 |
| Heavy alcohol use | 22 (14.6) | 1 (2.4) | .031 |
| Medications before admission | |||
| Anticoagulation therapy | 14 (8.6) | 2 (4.2) | .54 |
| Direct oral anticoagulant | 11 (78.6) | 0 (0) | |
| Warfarin | 3 (21.4) | 2 (100) | |
| Low-molecular-weight heparin | 0 (0) | 0 (0) | |
| Antiplatelet therapy | 25 (15.3) | 1 (2.1) | .030 |
| Aspirin | 20 (80) | 1 (100) | |
| P2Y12 inhibitor | 5 (20) | 0 (0) | |
| NSAIDs | 5 (3.1) | 0 (0) | .59 |
| Steroids | 8 (4.9) | 0 (0) | .20 |
| Other immunosuppression medication | 10 (6.2) | 0 (0) | .12 |
| Clinical presentation | <.001 | ||
| STEMI | 30 (18.3) | 0 (0) | |
| Stroke | 74 (45.1) | 8 (16.7) | |
| VTE | 60 (36.6) | 40 (83.3) | |
BMI, Body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; MI, myocardial infarction; NSAIDs, nonsteroidal anti-inflammatory drugs; STEMI, ST-segment myocardial infarction; VTE, venous thromboembolism.
Data presented as number (%) or median (interquartile range).